New combo therapy aims to deeply suppress multiple myeloma

NCT ID NCT04268498

Ongoing Disease control Sponsor: University of Miami Source: ClinicalTrials.gov ↗

First seen Apr 01, 2026 · Last updated May 15, 2026 · Updated 5 times

Summary

This study tests whether adding daratumumab to a standard three-drug regimen (carfilzomib, lenalidomide, dexamethasone) can better control multiple myeloma in newly diagnosed patients. About 310 participants will receive either the three-drug or four-drug combination. The main goal is to see if the extra drug leads to less detectable disease after eight treatment cycles.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Huntsman Cancer Institue

Salt Lake City, Utah, 84113, United States
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Moffitt Cancer Center

Tampa, Florida, 33612-9497, United States
Roswell Park Comprehensive Cancer Center

Buffalo, New York, 14203, United States
Stony Brook University

Stony Brook, New York, 11794, United States
University of Miami

Miami, Florida, 33136, United States

Conditions

Explore the condition pages connected to this study.

MULTIPLE MYELOMA